Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Genomics & Personalized Medicine Act
The old saying “if at first you don’t succeed, try, try again” is clearly evident with supporters of the Genomics and Personalized Medicine Act (GPMA). Rep. Anna Eshoo (D-CA) is working to introduce a fifth incarnation of the bill, details of which can be found here. She is trying to succeed where then Illinois senator Barack Obama and others have failed to get their versions of the GPMA legislation past committees. Rep. Eshoo is promising to reintroduce the bill in Congress by 2012, and President Obama would likely support a revived GPMA. A Congress eye-deep in budget wars, though, may not be as generous with tax credits and other funding as biotech advocates might want. What do you think are Rep. Eshoo’s chances of succeeding?